Skip to main content
RUA LIFE SCIENCES PLC logo

RUA LIFE SCIENCES PLC — Investor Relations & Filings

Ticker · RUA ISIN · GB0033360586 LEI · 213800BMVB22PVOJ9Z28 IL Manufacturing
Open in API
Filings indexed 200 across all filing types
Latest filing 2021-08-10 Board/Management Inform…
Country GB United Kingdom
Listing IL RUA

About RUA LIFE SCIENCES PLC

https://rualifesciences.com/

RUA Life Sciences is a medical device group focused on the application of its proprietary long-term implantable polymer, Elast-Eon™, a biostable polyurethane. The company operates through four integrated businesses to develop, manufacture, and license medical device solutions. RUA Biomaterials is responsible for licensing the Elast-Eon™ technology. RUA Medical provides end-to-end contract development and manufacturing services, specializing in implantable fabrics. RUA Vascular develops large-bore, polymer-sealed vascular grafts and soft tissue patches. RUA Structural Heart is engaged in the development of next-generation tri-leaflet polymeric heart valves. The group's collective mission is to improve patient outcomes by enabling and enhancing medical devices through its advanced polymer technology.

Recent filings

Filing Released Lang Actions
Directorate Change
Board/Management Information Classification · 1% confidence The document is an official announcement filed via RNS (RNS Number : 0709I) dated August 10, 2021. The primary subject is a 'Directorate Change' involving the retirement of the Group CEO and the withdrawal of a resolution related to his re-election at the forthcoming Annual General Meeting (AGM). Since the core content is announcing changes in senior management (CEO retirement, promotions, and planned future hires), it directly aligns with the definition of Board/Management Information (MANG). Although it mentions the AGM and withdrawal of a resolution, the main purpose is personnel change notification, not the AGM materials themselves (AGM-R) or the voting results (DVA). It is not a full financial report (10-K, IR) or an earnings release (ER).
2021-08-10 English
Full Year Results Investor Presentation
Report Publication Announcement Classification · 1% confidence The document is an RNS announcement dated July 13, 2021, titled "Full Year Results Investor Presentation" and announces an upcoming "Results Webinar" to cover the FY results for the year ended March 31, 2021. It provides registration links and contact details for the event. This document is not the full financial report (10-K or IR) itself, nor is it the formal earnings release (ER). Instead, it is an announcement specifically about an upcoming investor presentation/webinar related to the results. This aligns best with the 'Investor Presentation' (IP) category, as it is an announcement detailing an event where an investor presentation will be given. Although it is distributed via RNS, the specific content focus points strongly to IP over the general RNS fallback.
2021-07-13 English
Final Results
Earnings Release Classification · 1% confidence The document explicitly states it announces the 'Final results for the year ended 31 March 2021' and provides detailed financial highlights (Revenue, Operating loss, Year-end cash balances) and commentary from the Chairman and CEO regarding the past year's performance and future outlook. This structure is characteristic of a comprehensive annual financial report summary, often released alongside or as the primary content of a full Annual Report (10-K) or a preliminary Earnings Release (ER). Since it contains audited final results and extensive management discussion, it is more comprehensive than a simple ER. However, in the context of UK regulatory filings (indicated by the RNS Number and RUA Life Sciences PLC), this announcement serves as the primary disclosure of the full-year financial performance, which aligns best with the definition of an Annual Report (10-K) or a comprehensive Interim/Annual Report. Given the context of 'Final results' and the depth of financial detail, it is classified as an Annual Report (10-K), although in a non-US context, it functions as the primary annual filing. If a specific 'Annual Report' code existed for non-10-K filings, it might fit there, but 10-K is the closest fit for a full-year audited result disclosure. FY 2021
2021-07-12 English
Update on RUA Vascular
Regulatory Filings Classification · 1% confidence The document starts with an 'RNS Number' and is dated June 25, 2021. It provides an 'Update on RUA Vascular' concerning the preparation and delay of a 510k application to the FDA due to sample contamination. The text concludes with contact information and a standard disclaimer referencing RNS, the news service of the London Stock Exchange, and the Financial Conduct Authority (FCA). This structure is characteristic of a general regulatory news service announcement, which is not a full financial report (like 10-K or IR) or a specific corporate action announcement (like DIV or CAP). Since it is a general, timely update disseminated via the RNS system that doesn't fit the more specific categories (like DIRS, MANG, or ER), the most appropriate classification is the general regulatory filing fallback.
2021-06-25 English
Buy Back and Cancellation of Deferred Shares
Share Issue/Capital Change Classification · 1% confidence The document is an official announcement released via RNS (RNS Number : 0383D) on June 24, 2021. The core subject is the 'Buy Back and Cancellation of Deferred Shares'. This action directly relates to the company repurchasing and subsequently cancelling its own shares, which aligns precisely with the definition of 'Transaction in Own Shares'. Although it involves share capital changes, the specific action described (buy back and cancellation) makes 'POS' (Transaction in Own Shares) a more accurate classification than 'SHA' (Share Issue/Capital Change) or 'CAP' (Capital/Financing Update). The document is short and serves as a direct announcement of the transaction completion.
2021-06-24 English
GM Result, Issue of Equity & Total Voting Rights
Declaration of Voting Results & Voting Rights Announcements Classification · 1% confidence The document is an official announcement released via RNS (RNS Number: 8682C) on June 23, 2021. The key content revolves around the 'Results of General Meeting' and the subsequent 'Issue of Equity' and 'Total Voting Rights' update. Specifically, it details that all resolutions proposed at the General Meeting were passed, including an ordinary resolution authorizing a Buy Back Agreement and a special resolution adopting new Articles of Association. It concludes by stating the new total voting rights figure. This content directly relates to the outcomes of a shareholder vote and associated corporate actions, fitting the definition of 'Declaration of Voting Results & Voting Rights Announcements' (DVA). While it mentions the General Meeting, the focus is on the results and the resulting share capital change, not the proxy solicitation materials (PSI) or the AGM presentation itself (AGM-R). Since it is a formal announcement of voting results, DVA is the most precise fit.
2021-06-23 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.